Gofen painkiller capsules 400 mg, 60 pcs.
The side effects of ibuprofen and NSAIDs in general can be reduced by using the minimum effective dose needed to treat symptoms for a short period of time.
Elderly patients have an increased incidence of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal.
Effects on the respiratory system. Patients who suffer from bronchial asthma or allergic diseases or have a history of these diseases may experience bronchospasm.
Other NSAIDs. Concomitant use of ibuprofen with other NSAIDs, including selective COX-2 inhibitors, increases the risk of adverse reactions and should therefore be avoided.
Systemic lupus erythematosus and mixed connective tissue diseases. Ibuprofen should be used with caution in cases of systemic lupus erythematosus and mixed connective tissue diseases due to an increased risk of aseptic meningitis.
Metabolism of porphyrin. Caution should be exercised in patients with an inborn disorder of porphyrin metabolism (eg, acute intermittent porphyria).
Effect on the cardiovascular and cerebrovascular system. Patients with a history of arterial hypertension and/or heart failure should initiate treatment with caution (consult a physician), since cases of fluid retention, arterial hypertension and edema have been reported during therapy with ibuprofen, as with other NSAIDs.
Clinical trial and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg per day), may be associated with a slightly increased risk of arterial thrombotic complications (eg, myocardial infarction or stroke). In general, epidemiological studies do not suggest that low-dose ibuprofen (eg, ≤ 1200 mg per day) may lead to an increased risk of arterial thrombotic complications.
Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), known ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease should be treated with ibuprofen only after careful clinical evaluation. High doses (2400 mg per day) should be avoided.
The clinical picture should also be carefully assessed before initiating long-term treatment in patients with risk factors for cardiovascular complications (eg, hypertension, hyperlipidemia, diabetes mellitus, smoking), especially if high doses of ibuprofen (2400 mg per day) are required.
Effect on the kidneys. Ibuprofen should be used with caution in patients with renal impairment as renal function may deteriorate. Effect on the liver. Possible liver dysfunction.
Surgical interventions. Caution should be exercised immediately after major surgery. Effect on fertility in women. There is limited evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis, when used long-term (applies to a dose of 2400 mg per day, as well as treatment duration of more than 10 days), may impair fertility in women by affecting ovulation. This process is reversible after stopping treatment.
Effect on the gastrointestinal system. NSAIDs should be used with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), as these conditions may be exacerbated. There are reports of cases of gastrointestinal bleeding, perforation, ulcers, possibly fatal, that occurred at any stage of treatment with NSAIDs, regardless of the presence of warning symptoms or a history of severe gastrointestinal disorders.
The risk of gastrointestinal bleeding, perforation, and ulcers increases with increasing doses of NSAIDs in patients with a history of ulcers, especially those complicated by bleeding or perforation, and in elderly patients. Such patients should start with minimal doses. For such patients, as well as for those who require concomitant use of low doses of acetylsalicylic acid or other drugs that may increase gastrointestinal risk, the need for combination therapy with protective drugs (for example, misoprostol or proton pump inhibitors) should be considered.
Patients with a history of gastrointestinal disorders, especially elderly patients, should be informed of any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly at the start of treatment.
Caution should be exercised when treating patients receiving concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants (eg, warfarin), selective serotonin reuptake inhibitors, or antiplatelet agents (eg, aspirin).
In the event of gastrointestinal bleeding or ulceration in patients receiving ibuprofen, treatment should be discontinued immediately.
Effect on skin. Very rarely, severe skin reactions that can be fatal may occur with NSAIDs, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis. The highest risk of such reactions occurs in the early stages of therapy; in most cases, the onset of such reactions occurs during the first month of treatment. Ibuprofen should be discontinued at the first sign of skin rash, pathological changes in the mucous membranes, or any other signs of hypersensitivity.
In exceptional cases, chickenpox can cause severe infectious complications of the skin and soft tissues. At this time, the influence of NSAIDs in worsening these infections cannot be ruled out, so it is recommended to avoid ibuprofen in the case of chickenpox.
Allergy. Caution should be exercised in patients who have allergic reactions to other substances, as these patients also have an increased risk of developing hypersensitivity reactions when taking ibuprofen.
In patients suffering from hay fever, nasal polyps, chronic obstructive respiratory diseases, a history of allergic diseases, there is an increased risk of allergic reactions, which can manifest as asthma attacks (so-called analgesic asthma), Quincke's edema, urticaria.
This medicine contains sorbitol solution. Patients with a rare hereditary form of fructose intolerance, glucose-galactose malabsorption syndrome, and sucrase or isomaltase enzyme deficiency should not take this drug.
Other. Severe acute hypersensitivity reactions (eg anaphylactic shock) are very rare. At the first signs of a hypersensitivity reaction after using the drug, therapy should be discontinued. In such cases, it is necessary to carry out both symptomatic and specialized therapy.
Ibuprofen may temporarily suppress platelet function (affect platelet aggregation). Therefore, it is recommended to carefully monitor the condition of patients with bleeding disorders.
With long-term use of the drug, it is necessary to regularly check liver and kidney function indicators, as well as check the blood picture.
Long-term use of any painkillers to treat headaches may worsen the condition. If you suspect or confirm this situation, you should consult a doctor and stop treatment. A diagnosis of headache due to drug overuse should be considered in patients who suffer from frequent or daily headaches despite (or through) regular use of headache medications.
Routine use of painkillers, especially combinations of several painkillers, can lead to permanent impairment of kidney function with a risk of kidney failure (analgesic nephropathy). This risk may be increased due to salt loss and dehydration.
When using NSAIDs with concomitant alcohol consumption, the risk of adverse effects associated with the active substance, especially from the gastrointestinal tract or central nervous system, may increase.
GOFFEN
Side effects can be reduced by short-term use of the minimum effective dose required to treat symptoms. Elderly patients are at increased risk of adverse reactions from NSAID use, especially gastrointestinal bleeding and perforation, which can be fatal. Patients who currently have or have a history of bronchial asthma or allergic diseases may experience bronchospasm.
It should be used with caution in patients with: - systemic lupus erythematosus and systemic connective tissue diseases, since the risk of aseptic meningitis increases; - a history of arterial hypertension and/or heart failure, which were accompanied by fluid retention and edema when using non-steroidal anti-inflammatory drugs; - impaired renal and/or liver function.
This medicine contains sorbitol solution 70% (sorbitol), therefore patients with hereditary fructose intolerance are not recommended to use this medicine.
There is evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis may impair female fertility through effects on ovulation. This can be corrected by stopping these medications.
Nonsteroidal anti-inflammatory drugs should be used with caution in patients with a history of ulcerative colitis or Crohn's disease, as their condition may worsen. Gastrointestinal bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs and regardless of the duration of treatment, even without a history of serious gastrointestinal disease.
Increasing the dose of NSAIDs, older age and a history of peptic ulcers are at risk of adverse reactions from the digestive tract. During treatment in such cases, it is recommended to use the minimum effective dose of the drug.
Patients who have experienced gastrointestinal disorders, especially the elderly, should stop treatment and consult a doctor if any undesirable symptoms (especially bleeding from the digestive tract) occur.
If necessary, combination therapy with protective drugs (for example misoprostol or proton pump inhibitors) should be carried out, especially in patients who require long-term use of low doses of acetylsalicylic acid or other drugs that may lead to an increased risk of side effects from the gastrointestinal tract.
Use with caution in patients receiving concomitant therapy with drugs that may increase the risk of peptic ulcers or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid.
Serious skin reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may very rarely occur in association with the use of nonsteroidal anti-inflammatory drugs. The highest risk of these reactions occurs at the beginning of treatment, with the first manifestations appearing in most cases during the first month of treatment.
With long-term use of painkillers in large doses, headaches may occur, which cannot be treated by increasing the dose of the drug. Long-term and uncontrolled use of painkillers, especially a combination of different analgesic active ingredients, can lead to chronic kidney damage with the risk of renal failure (analgesic nephropathy).
